文献速递急性肾损伤

急性肾损伤的新型疗法

Novel Therapies for Acute Kidney Injury.
PubMed 文献 · Kidney Int Rep · 2017-06-28

急性肾损伤(AKI)病理生理复杂,传统支持治疗包括避免肾毒性药物、审慎容量和血压管理、血流动力学监测及肾脏替代治疗。液体超负荷和富氯液体与AKI发生相关,保守速率使用平衡缓冲液复苏可降低风险。新型疗法针对可观察的肾损伤模式,包括氧自由基清除剂、血管活性药物、抗炎药物及基因修饰剂等。

要点

  • 避免肾毒性药物、审慎容量和血压管理是AKI基础支持治疗。
  • 液体超负荷和富氯液体与AKI相关,平衡缓冲液保守复苏可降低风险。
  • 新型疗法靶向氧化应激、血流动力学、炎症及转录过程等机制。

核心结论

  • AKI治疗传统以支持为主,新型疗法针对特定可观察的肾损伤模式,包括氧自由基清除剂、血管活性药物、抗炎药物和基因修饰剂。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 液体超负荷和富氯液体与AKI发生相关,保守速率使用平衡缓冲液复苏可降低风险。
  • 直接氧自由基清除剂包括α-硫辛酸、姜黄素、2-巯基乙磺酸钠、丙泊酚和硒。
  • 血管紧张素II和腺苷受体拮抗剂通过调节肾血流动力学和管球反馈改善肾损伤。
  • 碱性磷酸酶、1-磷酸鞘氨醇类似物和二肽基肽酶-4抑制剂通过调节炎症通路对抗肾损伤。
  • 基因修饰剂如5INP可能通过转录过程减轻AKI。

临床怎么用

  • 临床应避免肾毒性药物,审慎管理容量和血压,监测血流动力学。
  • 复苏时考虑使用平衡缓冲液并采用保守速率,以减少AKI风险。
  • 新型疗法如氧自由基清除剂、血管活性药物等需进一步研究验证临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury (AKI) is a common disease with a complex pathophysiology. The old paradigm of identifying renal injury based on location-prerenal, intrarenal, and postrenal-is now being supplanted with a new paradigm based on observable kidney injury patterns. The pathophysiology of AKI on a molecular and microanatomical level includes inflammation, immune dysregulation, oxidative injury, and impaired microcirculation. Treatment has traditionally been supportive, including the avoidance of nephrotoxins, judicious volume and blood pressure management, hemodynamic monitoring, and renal replacement therapy. Fluid overload and chloride-rich fluids are now implicated in the development of AKI, and resuscitation with a balanced, buffered solution at a conservative rate will mitigate risk. Novel therapies, which address specific observable kidney injury patterns include direct oxygen-free radical scavengers such as α-lipoic acid, curcumin, sodium-2-mercaptoethane sulphonate, propofol, and selenium. In addition, angiotensin II and adenosine receptor antagonists hope to ameliorate kidney injury via manipulation of renal hemodynamics and tubulo-glomerular feedback. Alkaline phosphatase, sphingosine 1 phosphate analogues, and dipeptidylpeptidase-4 inhibitors counteract kidney injury via manipulation of inflammatory pathways. Finally, genetic modifiers such as 5INP may mitigate AKI via transcriptive processes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chen H, Busse LW. Novel Therapies for Acute Kidney Injury. Kidney Int Rep. 2017. PMID: 29270486. doi:10.1016/j.ekir.2017.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。